HIMS vs IMVT: Which Stock Is the Better Buy?
Hims & Hers Health, Inc. and Immunovant, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — HIMS vs IMVT, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Hims & Hers Health, Inc. (HIMS) | Immunovant, Inc. (IMVT) | |
|---|---|---|
| Market cap | $6.5B | $6.6B |
| Revenue (latest FY) | $2.35B | $0 |
| Net income (latest FY) | $128.37M | $-505.61M |
| Revenue growth (5y CAGR) | 73.6% | — |
| Net margin | 5.5% | — |
| Return on equity | 23.7% | -59.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full HIMS vs IMVT breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open HIMS's full financials → Open IMVT's full financials →More comparisons
Frequently asked questions
Which is bigger, HIMS or IMVT?
Immunovant, Inc. is larger by market capitalization — $6.6B versus $6.5B.
Which grows faster, HIMS or IMVT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.